1. In Vivo

Biopharma Quarterly Deal Statistics, Q1 2012

A look at financing, M&A, and alliance activity January–March 2012

Biopharma financing totaled $3.7 billion in Q1 2012, $1 billion more than the previous quarter. A total of 22 M&As – with a potential value of $9.28 billion – were completed. Acquisitions of private biotechs structured with earn-outs were a highlight. About a quarter of the alliances involved Big Pharmas, with GlaxoSmithKline and Novartis taking the lead.

The first quarter of 2012 featured $3.7 billion in biopharma financing, $1 billion more than Q4 2011’s total, but on pace with the opening quarter of last year, in which $3.6 billion was raised.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo